LIB Therapeutics

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, LIB Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 7 completed later-stage tilt upper quartile by trial count

LIB Therapeutics: 8 sponsored US clinical trials, none currently recruiting.

LIB Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 5 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is LDL Cholesterol, with 1 trials.

Upper-quartile sponsor footprint

LIB Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

NOT YET RECRUITING Phase 3

Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

NCT07102511
COMPLETED Phase 3

Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product

NCT05234775
COMPLETED Phase 3

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

NCT04797104
COMPLETED Phase 3

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

NCT04790513
COMPLETED Phase 3

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

NCT04034485
COMPLETED Phase 2

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

NCT03847974
COMPLETED Phase 2

Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

NCT03549260
COMPLETED Phase 1

Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

NCT03545438

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 5

Therapeutic Areas

LDL Cholesterol 1
Heterozygous Familial Hypercholesterolemia 1
Hypercholesterolemia 1

How the LIB Therapeutics archive is shaped

8 indexed studies, none listed as recruiting (0% open); 7 completed (88%).

Phase mix: 5 late (III/IV) vs 3 early (I/II) (later-stage heavy).

Top condition: LDL Cholesterol (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

LIB Therapeutics: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

LIB Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share LIB TherapeuticsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
LIB Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

LIB Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this LIB Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of LIB Therapeutics or any single study.

  • None of LIB Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • LDL Cholesterol is the condition LIB Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See LDL Cholesterol trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

LIB Therapeutics pipeline card: 8 registered trials from official public datasets.Report a data error.